Early Access Program (EAP) for avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
This Expanded Access Program is intended to provide access to avapritinib treatment for patients with locally advanced unresectable or metastatic GIST. Additionally, it aims to further characterize the safety and effectiveness of avapritinib.
GIST that carries a mutation in exon 18 of the PDGFRA gene
1. Patients 18 years and older
2. Patients with GIST that cannot be removed surgically and are not eligible for an ongoing study of avapritinib
Other eligibility criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
No minimum or maximum treatment duration has been set. Patients will be monitored at regular intervals for safety and for response to treatment.
Knight Clinical Trials Information Line
Blueprint Medicines Corporation